Shares of Shield Therapeutics plc (LON:STX – Get Free Report) reached a new 52-week low on Monday . The company traded as low as GBX 1.40 ($0.02) and last traded at GBX 1.43 ($0.02), with a volume of 705759 shares changing hands. The stock had previously closed at GBX 1.45 ($0.02).
Shield Therapeutics Trading Down 5.3 %
The stock’s fifty day simple moving average is GBX 2.43 and its 200 day simple moving average is GBX 4.99. The company has a quick ratio of 2.16, a current ratio of 2.95 and a debt-to-equity ratio of 21.30. The firm has a market capitalization of £10.56 million, a PE ratio of -11.67 and a beta of 0.84.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- 3 Technologies to Challenge NAND Flash Dominance in AI
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Is Zoom Video Stock Getting Too Cheap to Pass Up?
- Dividend Payout Ratio Calculator
- Packaging Corporation of America: Buy The Dip
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
